These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23469177)

  • 1. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
    Nara M; Teshima K; Watanabe A; Ito M; Iwamoto K; Kitabayashi A; Kume M; Hatano Y; Takahashi N; Iida S; Sawada K; Tagawa H
    PLoS One; 2013; 8(3):e56954. PubMed ID: 23469177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
    Fan JL; Zhang J; Dong LW; Fu WJ; Du J; Shi HG; Jiang H; Ye F; Xi H; Zhang CY; Hou J; Wang HY
    Cell Death Dis; 2014 Mar; 5(3):e1126. PubMed ID: 24625985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection for therapeutic targets specifically expressed in myeloma side population cells].
    Tagawa H
    Nihon Rinsho; 2014 Jun; 72(6):1052-7. PubMed ID: 25016803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
    Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
    Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
    J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
    Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
    Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib Is More Effective to Side Population of RPMI8226 Myeloma Cells than Classical Anti-myeloma Agents.
    Kim KH; Cheong HJ; Lee MY; Lee N; Lee KT; Park SK; Won JH
    Anticancer Res; 2019 Jan; 39(1):127-133. PubMed ID: 30591449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
    McMillin DW; Jacobs HM; Delmore JE; Buon L; Hunter ZR; Monrose V; Yu J; Smith PG; Richardson PG; Anderson KC; Treon SP; Kung AL; Mitsiades CS
    Mol Cancer Ther; 2012 Apr; 11(4):942-51. PubMed ID: 22246439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
    Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
    Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
    Kawano Y; Kikukawa Y; Fujiwara S; Wada N; Okuno Y; Mitsuya H; Hata H
    Int J Oncol; 2013 Dec; 43(6):1809-16. PubMed ID: 24126540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
    de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
    PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
    Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
    Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
    Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA; Lonial S; Boise LH; Bahlis NJ
    Blood; 2011 Dec; 118(24):6368-79. PubMed ID: 21917757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis.
    Park J; Bae EK; Lee C; Choi JH; Jung WJ; Ahn KS; Yoon SS
    BMB Rep; 2014 May; 47(5):274-9. PubMed ID: 24286313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
    Gaudichon J; Milano F; Cahu J; DaCosta L; Martens AC; Renoir JM; Sola B
    PLoS One; 2014; 9(9):e107009. PubMed ID: 25255316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.